Condition: Crohn's Disease (CD) · Sponsor: Takeda
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive either a high dose or low dose of vedolizumab once every 8 weeks. They will receive the same dose every time.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| Phoenix Childrens Hospital | Phoenix, Arizona, United States | Not Yet Recruiting |
| Cedars Sinai Medical Center | Los Angeles, California, United States | Withdrawn |
| Rady Childrens Hospital San Diego - PIN | San Diego, California, United States | Not Yet Recruiting |
| University of California San Francisco | San Francisco, California, United States | Withdrawn |
| I.H.S Health LLC | Kissimmee, Florida, United States | Withdrawn |
| Childrens Center For Digestive Healthcare | Atlanta, Georgia, United States | Recruiting |
| Advocate Children's Hospital Park Ridge | Park Ridge, Illinois, United States | Recruiting |
| Riley Hospital For Children | Indianapolis, Indiana, United States | Withdrawn |
| Johns Hopkins University | Baltimore, Maryland, United States | Not Yet Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| MNGI Digestive Health, PA | Minneapolis, Minnesota, United States | Recruiting |
| Mayo Clinic - PIN | Rochester, Minnesota, United States | Not Yet Recruiting |
+ 84 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04779320